相关实验视频

Updated: Mar 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

莱波迪西兰:关于新型和新兴脂蛋白 (a) 降低剂的最新评论

Manuel Urina-Jassir¹, Kevin Tong², Alexander Stanisic²

¹From the Department of Medicine, Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.

Cardiology in review

|March 4, 2026

概括

升高的脂蛋白 (a) 是心血管疾病的危险因素. 利波迪西兰是一种新型RNA疗法,有效降低脂蛋白 (a),目前正在进行的临床试验中对心血管事件减少进行评估.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

升高的脂蛋白 (a) [Lp(a) ]是动脉样硬化心血管疾病 (ASCVD) 的独立危险因素.
升高的Lp (a) 的高患病率对ASCVD的全球负担作出了重大贡献.
针对Lp (a) 的新型治疗策略对于ASCVD预防至关重要.

研究的目的:

为提供lepodisiran的最新审查,一种针对Lp(a) 的新型RNA治疗剂.
总结莱波迪西兰已完成的临床试验中的安全性和有效性研究结果.
描述正在进行的第三阶段ACCLAIM-Lp试验的设计和目标.

主要方法:

从第一阶段,第二阶段随机对照试验 (RCT) 评估勒波迪西兰安全性和疗效的已公布数据的审查.
分析了ALPACA第二阶段试验的结果,评估了Lp (a) 减少.
描述ACCLAIM-Lp (a) 3期RCT设计,重点关注心血管事件的结果.

主要成果:

勒波迪西兰在第一期和第二期试验中表现出良好的安全性.
第二阶段研究证实了勒波迪西兰在降低Lp (a) 水平方面的显著有效性.
目前正在进行的第三期试验旨在评估高风险患者的主要心血管事件.

结论:

勒波迪西兰是降低ASCVD风险患者Lp (a) 的有希望的治疗选择.
预计来自ACCLAIM-Lp (a) 试验的进一步数据将证实其在减少心血管事件方面的临床益处.
用莱波迪西兰等药物向Lp (a) 具有ASCVD风险管理的潜力.

关键词:

过高脂血症是什么意思莱波迪斯兰 (Lepodisiran) 是一个脂质学脂质学是指脂质学脂蛋白 (a) 是一种蛋白质.预防性心脏病学预防性心脏病学

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...